Literature DB >> 12754715

Interim analysis of continuous long-term endpoints in clinical trials with longitudinal outcomes.

Sally Galbraith1, Ian C Marschner.   

Abstract

This paper discusses interim analysis for clinical trials where the primary endpoint is observed at a specific long-term follow-up time, but where repeated measures of the same outcome are also taken at earlier times. Methods are considered for improving the efficiency with which the long-term treatment difference is estimated, making use of information from shorter-term follow-up times. This approach to interim analysis has previously been studied for binary endpoints assessed at two time points during follow-up. Here we adapt and extend this methodology to include continuous endpoints assessed at an arbitrary number of follow-up times, making use of methods for analysing multivariate normal data subject to monotone missingness and unstructured mean and covariance relationships. The magnitude of efficiency gains obtained by using short-term measurements is considered, as well as how these gains depend on the number and timing of the short-term measurements. Sequential analysis of treatment differences is discussed, including the extent to which efficiency gains translate into reductions in the expected duration of a sequentially monitored trial. The methods are illustrated on a data set involving a placebo-controlled comparison of longitudinal cholesterol measurements. Copyright 2003 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12754715     DOI: 10.1002/sim.1311

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  7 in total

1.  Data-driven treatment selection for seamless phase II/III trials incorporating early-outcome data.

Authors:  Cornelia Ursula Kunz; Tim Friede; Nick Parsons; Susan Todd; Nigel Stallard
Journal:  Pharm Stat       Date:  2014-05-02       Impact factor: 1.894

2.  Blinded versus unblinded estimation of a correlation coefficient to inform interim design adaptations.

Authors:  Cornelia U Kunz; Nigel Stallard; Nicholas Parsons; Susan Todd; Tim Friede
Journal:  Biom J       Date:  2016-11-25       Impact factor: 2.207

3.  An adaptive two-arm clinical trial using early endpoints to inform decision making: design for a study of sub-acromial spacers for repair of rotator cuff tendon tears.

Authors:  Nick Parsons; Nigel Stallard; Helen Parsons; Philip Wells; Martin Underwood; James Mason; Andrew Metcalfe
Journal:  Trials       Date:  2019-12-09       Impact factor: 2.279

4.  Group sequential designs in pragmatic trials: feasibility and assessment of utility using data from a number of recent surgical RCTs.

Authors:  Nick R Parsons; Nigel Stallard; Helen Parsons; Aminul Haque; Martin Underwood; James Mason; Iftekhar Khan; Matthew L Costa; Damian R Griffin; James Griffin; David J Beard; Jonathan A Cook; Loretta Davies; Jemma Hudson; Andrew Metcalfe
Journal:  BMC Med Res Methodol       Date:  2022-10-01       Impact factor: 4.612

5.  Advancing clinical trial design in pulmonary hypertension.

Authors:  Andy P Grieve; Shien-Chung Chow; John Curram; Stephen Dawe; Lutz O Harnisch; Noreen R Henig; Hsien Ming J Hung; D Dunbar Ivy; Steven M Kawut; Mohammad H Rahbar; Shen Xiao; Martin R Wilkins
Journal:  Pulm Circ       Date:  2013-01       Impact factor: 3.017

6.  A comparison of methods for treatment selection in seamless phase II/III clinical trials incorporating information on short-term endpoints.

Authors:  Cornelia Ursula Kunz; Tim Friede; Nicholas Parsons; Susan Todd; Nigel Stallard
Journal:  J Biopharm Stat       Date:  2015       Impact factor: 1.051

7.  Combined assessment of early and late-phase outcomes in orphan drug development.

Authors:  Konstantinos Pateras; Stavros Nikolakopoulos; Kit C B Roes
Journal:  Stat Med       Date:  2021-04-04       Impact factor: 2.373

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.